GLP-1 medications like Ozempic, Wegovy, and Zepbound have changed weight management and type 2 diabetes care. This video uses ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist ...

Patients with asthma using this weight loss drug ‘may have fewer attacks’ - Connection to reduced asthma or COPD flare-ups ...

A new study has found that semaglutide may have benefits beyond weight loss and blood sugar control. Researchers found that the drug slowed several signs of ageing and extended lifespan in older ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...

Among patients with type 2 diabetes and tobacco use disorder (TUD), use of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) was associated with a reduced risk of medical encounters for TUD ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...